FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313432073> ?p ?o ?g. }

• W4313432073 endingPage "28" @default.
• W4313432073 startingPage "18" @default.
• W4313432073 abstract "Dexmedetomidine is a centrally acting alpha-2A adrenergic agonist that is commonly used as a sedative and anxiolytic in the intensive care unit (ICU), with prolonged use increasing risk of withdrawal symptoms upon sudden discontinuation. As clonidine is an enterally available alpha-2A adrenergic agonist, it may be a suitable agent to taper off dexmedetomidine and reduce withdrawal syndromes. The appropriate dosing and conversion strategies for using enteral clonidine in this context are not known. The objective of this systematic review is to summarize the evidence of enteral clonidine application during dexmedetomidine weaning for prevention of withdrawal symptoms.To systematically review the practice, dosing schema, and outcomes of enteral clonidine use during dexmedetomidine weaning in critically ill adults.This was a systematic review of enteral clonidine used during dexmedetomidine weaning in critically ill adults (≥ 18 years). Randomized controlled trials, prospective cohorts, and retrospective cohorts evaluating the use of clonidine to wean patients from dexmedetomidine in the critically ill were included. The primary outcomes of interest were dosing and titration schema of enteral clonidine and dexmedetomidine and risk factors for dexmedetomidine withdrawal. Other secondary outcomes included prevalence of adverse events associated with enteral clonidine use, re-initiation of dexmedetomidine, duration of mechanical ventilation, and ICU length of stay.A total of 3427 studies were screened for inclusion with three meeting inclusion criteria with a total of 88 patients. All three studies were observational, two being prospective and one retrospective. In all included studies, the choice to start enteral clonidine to wean off dexmedetomidine was made at the discretion of the physician. Weaning time ranged from 13 to 167 h on average. Enteral clonidine was started in the prospective studies in a similar protocolized method, with 0.3 mg every 6 h. After starting clonidine, patients remained on dexmedetomidine for a median of 1-28 h. Following the termination of dexmedetomidine, two trials tapered enteral clonidine by increasing the interval every 24 h from 6 h to 8h, 12h, and 24 h, followed by clonidine discontinuation. For indicators of enteral clonidine withdrawal, the previously tolerable dosage was reinstated for several days before resuming the taper on the same protocol. The adverse events associated with enteral clonidine use were higher than patients on dexmedetomidine taper alone with increased agitation. The re-initiation of dexmedetomidine was not documented in any study. Only 17 (37%) patients were mechanically ventilated with median duration of 3.5 d for 13 patients in one of the 2 studies. ICU lengths of stay were similar.Enteral clonidine is a strategy to wean critically ill patients from dexmedetomidine. There is an association of increased withdrawal symptoms and agitation with the use of a clonidine taper." @default.
• W4313432073 created "2023-01-06" @default.
• W4313432073 creator A5007144339 @default.
• W4313432073 creator A5025259402 @default.
• W4313432073 creator A5029979353 @default.
• W4313432073 creator A5041651992 @default.
• W4313432073 creator A5044275206 @default.
• W4313432073 creator A5063841500 @default.
• W4313432073 creator A5075143461 @default.
• W4313432073 creator A5082706495 @default.
• W4313432073 date "2023-01-09" @default.
• W4313432073 modified "2023-09-27" @default.
• W4313432073 title "Clonidine use during dexmedetomidine weaning: A systematic review" @default.
• W4313432073 cites W1505219599 @default.
• W4313432073 cites W1969334283 @default.
• W4313432073 cites W1989359828 @default.
• W4313432073 cites W2000619195 @default.
• W4313432073 cites W2021342428 @default.
• W4313432073 cites W2038370375 @default.
• W4313432073 cites W2042617602 @default.
• W4313432073 cites W2050748489 @default.
• W4313432073 cites W2053993620 @default.
• W4313432073 cites W2081972845 @default.
• W4313432073 cites W2082311304 @default.
• W4313432073 cites W2089942661 @default.
• W4313432073 cites W2135672238 @default.
• W4313432073 cites W2142271203 @default.
• W4313432073 cites W2145624064 @default.
• W4313432073 cites W2159021223 @default.
• W4313432073 cites W2201842643 @default.
• W4313432073 cites W2406704086 @default.
• W4313432073 cites W2531269403 @default.
• W4313432073 cites W2778204866 @default.
• W4313432073 cites W2885896746 @default.
• W4313432073 cites W2946603992 @default.
• W4313432073 cites W2968559954 @default.
• W4313432073 cites W3008070940 @default.
• W4313432073 cites W3019350884 @default.
• W4313432073 cites W3097570152 @default.
• W4313432073 cites W3118615836 @default.
• W4313432073 cites W3215066433 @default.
• W4313432073 cites W630657035 @default.
• W4313432073 doi "https://doi.org/10.5492/wjccm.v12.i1.18" @default.
• W4313432073 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36683967" @default.
• W4313432073 hasPublicationYear "2023" @default.
• W4313432073 type Work @default.
• W4313432073 citedByCount "0" @default.
• W4313432073 crossrefType "journal-article" @default.
• W4313432073 hasAuthorship W4313432073A5007144339 @default.
• W4313432073 hasAuthorship W4313432073A5025259402 @default.
• W4313432073 hasAuthorship W4313432073A5029979353 @default.
• W4313432073 hasAuthorship W4313432073A5041651992 @default.
• W4313432073 hasAuthorship W4313432073A5044275206 @default.
• W4313432073 hasAuthorship W4313432073A5063841500 @default.
• W4313432073 hasAuthorship W4313432073A5075143461 @default.
• W4313432073 hasAuthorship W4313432073A5082706495 @default.
• W4313432073 hasBestOaLocation W43134320731 @default.
• W4313432073 hasConcept C126322002 @default.
• W4313432073 hasConcept C177713679 @default.
• W4313432073 hasConcept C2776376669 @default.
• W4313432073 hasConcept C2776814716 @default.
• W4313432073 hasConcept C2777288759 @default.
• W4313432073 hasConcept C2777602617 @default.
• W4313432073 hasConcept C2778399450 @default.
• W4313432073 hasConcept C2781302539 @default.
• W4313432073 hasConcept C2987404301 @default.
• W4313432073 hasConcept C42219234 @default.
• W4313432073 hasConcept C44315111 @default.
• W4313432073 hasConcept C71924100 @default.
• W4313432073 hasConcept C78722104 @default.
• W4313432073 hasConceptScore W4313432073C126322002 @default.
• W4313432073 hasConceptScore W4313432073C177713679 @default.
• W4313432073 hasConceptScore W4313432073C2776376669 @default.
• W4313432073 hasConceptScore W4313432073C2776814716 @default.
• W4313432073 hasConceptScore W4313432073C2777288759 @default.
• W4313432073 hasConceptScore W4313432073C2777602617 @default.
• W4313432073 hasConceptScore W4313432073C2778399450 @default.
• W4313432073 hasConceptScore W4313432073C2781302539 @default.
• W4313432073 hasConceptScore W4313432073C2987404301 @default.
• W4313432073 hasConceptScore W4313432073C42219234 @default.
• W4313432073 hasConceptScore W4313432073C44315111 @default.
• W4313432073 hasConceptScore W4313432073C71924100 @default.
• W4313432073 hasConceptScore W4313432073C78722104 @default.
• W4313432073 hasIssue "1" @default.
• W4313432073 hasLocation W43134320731 @default.
• W4313432073 hasLocation W43134320732 @default.
• W4313432073 hasLocation W43134320733 @default.
• W4313432073 hasOpenAccess W4313432073 @default.
• W4313432073 hasPrimaryLocation W43134320731 @default.
• W4313432073 hasRelatedWork W1593783008 @default.
• W4313432073 hasRelatedWork W2110127181 @default.
• W4313432073 hasRelatedWork W2373185700 @default.
• W4313432073 hasRelatedWork W3087305540 @default.
• W4313432073 hasRelatedWork W3172800307 @default.
• W4313432073 hasRelatedWork W3177300223 @default.
• W4313432073 hasRelatedWork W4241828112 @default.
• W4313432073 hasRelatedWork W4289531850 @default.
• W4313432073 hasRelatedWork W4385632352 @default.

• next